Reflux esophagitis
Conditions
Interventions
Oral administration of omeprazole (20mg) for 56 days
Sponsors
Department of Gastroenterology, Kobe University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients who have gave a written consent to participate in this study (2) Patients who were diagnosed as having erosive reflux esophagitis previously (3) Patients who are receiving rabeprazole 10mg per day for more than 8 weeks (4) Patients whose score of Frequency scale for symptoms of gastroesophageal reflux diseases (FSSG) are 8 or more points
Exclusion criteria
Exclusion criteria: (1) Patients with the past history of digestive tract excisio and vagotomy (2) Patients who have alert symptoms such as nausea, gastrointestinal bleeding and rapid weight loss (3) Patients who have past history of or suffer from the following diseases: Zollinger-Ellison symdrome, inflammatory bowel disease, esophageal stenosis, achalasia, malabsorption, cerebrovascular disease such as cerebral hemorrhage or cerebral infarction (4) Patients having severe liver, kidney or heart disease (5) Patients who have malignancy or are suspected of having malignancy (6) Patients who are pregnant, in breast-feeding or may have cecome pregnant (7) Patients who need continuous medication of atazanavir sulfate, diazepam, phenytoin, warfarin, tacrolimus, digoxin, methyldigoxin, itraconazole, Gefinitinib or voriconazole that might interact with the test drug (8) Patients who are receiving proton pump inhibitors except rabeprazole (9) Patients whom the doctor in charge judged to be unsuitable as an object of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in scores of Frequency scale for symptoms of gastroesophageal reflux diseases (FSSG) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Changes in scores of gastrointestinal symptom rating scale (GSRS) 2)Subgroup analysis for CYP2C19 genotype | — |
Countries
Japan
Outcome results
None listed